Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Conclusions Combined with a progestin, E4 adequately suppresses ovarian activity, particularly when given at a dosage above 10 mg/day. Chinese Abstract -。 1835、,II,。24/4-,510/3;5,1020/150 μg;20 μg/3。13,,、、-。,。 109。。:20,/。。1721,。。 ,10/。 ;;;;. PMID: 26394847 [PubMed - in process] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - September 25, 2015 Category: Reproduction Medicine Authors: Duijkers IJ, Klipping C, Zimmerman Y, Appels N, Jost M, Maillard C, Mawet M, Foidart JM, Coelingh Bennink HJ Tags: Eur J Contracept Reprod Health Care Source Type: research

Continues Norethisterone Acetate versus Cyclical Drospirenone 3 mg/ethinyl Estradiol 20 μg for the Management of Primary Dysmenorrhea in Young Adult Females
To evaluate the efficacy of continues Norethisterone acetate, 5 mg (NET-A; group N) versus cyclical combined oral contraceptive pill (COC) consisting of drospirenone 3 mg/ethinyl estradiol 20 μg pills (group P) in treating dysmenorrhea in young adult females. (Source: Journal of Pediatric and Adolescent Gynecology)
Source: Journal of Pediatric and Adolescent Gynecology - September 2, 2015 Category: OBGYN Authors: Moamar Al-Jefout, Nedal Nawaiseh Source Type: research

Continuous Norethisterone Acetate versus Cyclical Drospirenone 3 mg/Ethinyl Estradiol 20 μg for the Management of Primary Dysmenorrhea in Young Adult Women
To evaluate the efficacy of continuous norethisterone acetate (NET-A), 5 mg (group N) vs cyclical combined oral contraceptive pill (COC) consisting of drospirenone 3 mg/ethinyl estradiol 20 μg pills (group P) in treating dysmenorrhea in young adult women. (Source: Journal of Pediatric and Adolescent Gynecology)
Source: Journal of Pediatric and Adolescent Gynecology - September 2, 2015 Category: OBGYN Authors: Moamar Al-Jefout, Nedal Nawaiseh Tags: Original Study Source Type: research

Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin.
CONCLUSIONS Apelin level significantly increased in PCOS patients. The combined therapy of DRSP-EE plus metformin not only decreases IR, but also improves apelin level. This combination is a superior approach for PCOS treatment. PMID: 26314870 [PubMed - in process] (Source: Medical Science Monitor)
Source: Medical Science Monitor - September 1, 2015 Category: Research Tags: Med Sci Monit Source Type: research

Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol
CONCLUSIONSA moderate pharmacokinetic drug‐drug interaction between DRSP and KTZ was demonstrated in this study. No relevant changes of medical concern were detected in the safety data collected in this study. This article is protected by copyright. All rights reserved. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - August 14, 2015 Category: Drugs & Pharmacology Authors: Herbert Wiesinger, Matthias Berse, Stefan Klein, Simone Gschwend, Joachim Höchel, Frank S. Zollmann, Barbara Schütt Tags: Drug Interactions Source Type: research

A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen.
Conclusions The new drospirenone-only pill inhibited ovulation as effectively as the desogestrel-only pill despite the 4-day hormone-free interval. PMID: 26073333 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - June 15, 2015 Category: Reproduction Medicine Authors: Duijkers IJ, Heger-Mahn D, Drouin D, Skouby S Tags: Eur J Contracept Reprod Health Care Source Type: research

Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review.
Conclusion E2/NOMAC exhibits less haemostatic and metabolic impact than EE/LNG and other COCs, suggesting that it may be a promising candidate to reduce residual VTE risk associated with COC use. Confirmation from a well-powered prospective clinical trial is, however, needed. PMID: 26007631 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - May 26, 2015 Category: Reproduction Medicine Authors: Lete I, Chabbert-Buffet N, Jamin C, Lello S, Lobo P, Nappi RE, Pintiaux A Tags: Eur J Contracept Reprod Health Care Source Type: research

Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial
Conclusion A contraceptive containing 20mcg of ethinyl estradiol and 3mg of drospirenone causes no significant changes in clinical, hemodynamic and autonomic parameters of normal women. (Source: European Journal of Obstetrics and Gynecology and Reproductive Biology)
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - March 22, 2015 Category: OBGYN Source Type: research

Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea.
Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. Eur J Contracept Reprod Health Care. 2015 Feb 25;:1-12 Authors: Witjes H, Creinin MD, Sundström-Poromaa I, Martin Nguyen A, Korver T Abstract Objectives To compare premenstrual and menstrual symptoms in healthy women using nomegestrol acetate/17β-estradiol (NOMAC/E2) and drospirenone/ethinylestradiol (DRSP/EE) via the Moos Menstrual Distress Questionnaire Form C (MDQ-C). Methods Women completed the MDQ-C at baseline and afte...
Source: The European Journal of Contraception and Reproductive Health Care - February 25, 2015 Category: Reproduction Medicine Authors: Witjes H, Creinin MD, Sundström-Poromaa I, Martin Nguyen A, Korver T Tags: Eur J Contracept Reprod Health Care Source Type: research

Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study
Gynecological Endocrinology, Ahead of Print. (Source: Gynecological Endocrinology)
Source: Gynecological Endocrinology - February 23, 2015 Category: Endocrinology Tags: article Source Type: research

Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age
Conclusion A contraceptive containing 20mcg of ethinyl estradiol and 3mg of drospirenone causes no significant changes in clinical and autonomic parameters, metabolic variables and neurohumoral axis of hypertensive women. (Source: European Journal of Obstetrics and Gynecology and Reproductive Biology)
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - November 18, 2014 Category: OBGYN Source Type: research

Effects of estradiol-drospirenone on menopausal symptoms, lipids and bone turnover in Chinese women.
Abstract ABSTRACT Objective To investigate the effects of a hormone replacement preparation containing 1 mg estradiol plus 2 mg drospirenone on menopausal symptoms, blood lipids, and bone turnover markers in postmenopausal women. Methods A prospective, self-controlled trial was conducted in 64 Chinese postmenopausal women aged 45-60 (mean 52.5 ± 3.37) years who were treated with estradiol-drospirenone for at least 6 months. The Kupperman index, blood lipid concentrations, bone mineral density, and bone turnover markers were measured before (baseline) and at 1, 3, and 6 months after treatment. Results In com...
Source: Climacteric - November 3, 2014 Category: Geriatrics Authors: Li M, Wang A, Hu L, Song Z, Zhao Y, Sun Y, Yan L, Li X Tags: Climacteric Source Type: research

The comparative study of Yaz and Ovocept-ld on patients with simple ovarian cysts referring to Iran-Isfahan Shariati Hospital.
Abstract BACKGROUND: Functional ovarian cysts include follicular, corpus luteum, and theca lutein cysts are the most common adnexal masses (about 50%) in women of reproductive age. Treatment with the combined monophasic oral contraceptives reduces functional ovarian cysts. Yaz (drospirenone/ethinyl estradiol) is a low-dose combined oral contraceptive pill containing 20 μg ethinyl estradiol and 3 mg drospirenone. In addition to contraceptive effects, Yaz has anti-mineralocorticoid and anti-adrenergic effects. Ovocept- low-dose LD is also a low-dose combined oral contraceptive drug containing 30 μg ethinyl est...
Source: Biomed Res - October 27, 2014 Category: Research Authors: Riahinejad S, Pour AF, Dehghani L, Hajizadeh S Tags: Adv Biomed Res Source Type: research

A randomized phase III study comparing a new 13.5 mg levonorgestrel intrauterine contraceptive system with a combined oral contraceptive: analysis of efficacy and bleeding profiles
To compare contraceptive efficacy and bleeding profiles associated with use of the 13.5 mg (total content) levonorgestrel intrauterine contraceptive system (LNG-IUS13.5mg) and a 30 μg ethinyl estradiol and 3 mg drospirenone combined oral contraceptive (COC) in younger women. (Source: Fertility and Sterility)
Source: Fertility and Sterility - September 1, 2014 Category: Reproduction Medicine Authors: L. Borgatta, K. Roth, S. Rybowski, K. Rosen Source Type: research

Comparative study of the therapeutic effects of two different dosages of ethinyl estradiol (EE: 20 MCG versus 30 MCG) in association with drospirenone (DRSP: 3 mg) in polycystic ovary syndrome (PCOS)
To compare the therapeutic effects of two different dosages of Ethinyl estradiol (EE: 20 mcg versus 30 mcg) in combination with Drospirenone (DRSP: 3 mg) in polycystic ovary syndrome (PCOS) after 6 and 12 months of treatment. (Source: Fertility and Sterility)
Source: Fertility and Sterility - September 1, 2014 Category: Reproduction Medicine Authors: S.M. Bhattacharya, A. Jha Source Type: research

A multicenter, randomized phase III study comparing a 13.5 mg levonorgestrel intrauterine contraceptive system with a combined oral contraceptive: analysis of user satisfaction and safety
To compare user satisfaction and adverse events (AEs) with use of the 13.5 mg total content levonorgestrel intrauterine contraceptive system (LNG-IUS13.5mg) and a 30 μg ethinyl estradiol/3 mg drospirenone combined oral contraceptive (COC). (Source: Fertility and Sterility)
Source: Fertility and Sterility - September 1, 2014 Category: Reproduction Medicine Authors: L. Borgatta, K. Roth, S. Rybowski, K. Rosen Source Type: research

Low-dose oral or non-oral hormone therapy: effects on CRP and atrial natriuretic peptide in menopause.
Abstract ABSTRACT Objective. To assess the effects of oral low-dose and non-oral hormone therapy (HT) on ultra-sensitive C reactive protein (CRP), atrial natriuretic peptide (ANP), and cardiovascular risk factors in postmenopause. Methods. In this randomized crossover study, forty-four recent postmenopausal women, with no clinical evidence of cardiovascular disease, received oral low-dose HT (estradiol 1mg + drospirenone 2 mg/day) for 3 months. Forty-two patients received non-or al conventional HT (1.5 mg/day percutaneous 17β estradiol gel or equivalent for nasal route) for 3 months followed by 200 mg/day mic...
Source: Climacteric - July 12, 2014 Category: Geriatrics Authors: Casanova G, Reis AM, Spritzer PM Tags: Climacteric Source Type: research

Effects of hormone replacement therapy on plasma and tissue fibrinolytic activity in a rat model of surgically induced menopause.
Conclusions: HRT showed beneficial effects by decreasing fibrinolytic activity related to surgically-induced menopause. Short-term HRT treatment was associated with a shift in the procoagulant-anticoagulant balance toward a procoagulant state. PMID: 24690423 [PubMed - in process] (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - April 4, 2014 Category: Biomedical Science Authors: Topcuoglu A, Albayrak M, Erman H, Balci H, Karakus M, Coban I, Uzun H Tags: Clin Invest Med Source Type: research

Comparison of the Impact of Four Generations of Progestins on Hemostatic Variables
This study was undertaken to evaluate the impact of progestins as part of low-estrogen (ethinyl estradiol [EE2] ≤35 μg) combined oral contraceptives (COCs) on hemostatic variables. One hundred ninety-five healthy women took oral contraceptives with following formulations: 35 EE2/norgestimate (NGM), 35 EE2/cyproterone acetate, 35 EE2/norethisterone, 30 EE2/levonorgestrel, 30 EE2/drospirenone (DRSP), 20 EE2/gestodene, and 20 EE2/DRSP, for 6 months. Hemostatic assays (prothrombin time, activated partial thromboplastin time, fibrinogen, resistance to activated protein C ratio, protein C, protein S, factor VIII [FVIII], a...
Source: Clinical and Applied Thrombosis/Hemostasis - April 2, 2014 Category: Hematology Authors: Oslakovic, S., Zadro, R. Tags: Original Articles Source Type: research

Acne vulgaris in the context of complex medical co-morbities: The Management of Severe Acne Vulgaris in a Female with Retinitis Pigmentosa- Utilizing Pulse Dye Laser in Conjunction with Medical Therapy.
We present a patient with severe acne vulgaris and a history of retinitis pigmentosa who was treated with 595 nanometer pulsed dye laser therapy, in conjunction with therapeutic alternatives to first-line acne medications. Our patient exhibited a significant and sustained improvement with the combined use of 595 nanometer pulsed dye laser, Yaz (drospirenone-ethinyl estradiol), dapsone, topical metronidazole, sodium-sulfacetamide wash, and topical azelaic acid. The positive results in this case, suggest that this combined treatment modality may serve as an example of a safe and effective treatment alternative in the managem...
Source: Dermatol Online J - March 28, 2014 Category: Dermatology Authors: Shariff A, Keck L, Zlotoff B Tags: Dermatol Online J Source Type: research

The Effectiveness of Yaz and Yasmin Administered Orally and Vaginally for the Primary Treatment of Premenstrual Dysphoric Disorder
The objective of this study was to determine if Yaz and Yasmin when adminstered orally or vaginally exhibit similar effectiveness based on the daily record of severity problems scale. (Source: Journal of Pediatric and Adolescent Gynecology)
Source: Journal of Pediatric and Adolescent Gynecology - March 5, 2014 Category: OBGYN Authors: Jennifer Kurkowski, Jennifer E. Dietrich Tags: Poster Abstracts Source Type: research

Clitoral Vascularization and Sexual Behavior in Young Patients Treated with Drospirenone–Ethinyl Estradiol or Contraceptive Vaginal Ring: A Prospective, Randomized, Pilot Study
ConclusionsSix‐month treatment with hormonal contraception is associated with a diminished MFSQ score. However, the frequency of sexual intercourse and orgasm was reduced only by the use of OC. The OC use was associated with increased pain during intercourse. Battaglia C, Morotti E, Persico N, Battaglia B, Busacchi P, Casadio P, Paradisi R, and Venturoli S. Clitoral vascularization and sexual behavior in young patients treated with drospirenone–ethinyl estradiol or contraceptive vaginal ring: A prospective, randomized, pilot study. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)
Source: The Journal of Sexual Medicine - December 1, 2013 Category: Sexual Medicine Authors: Cesare Battaglia, Elena Morotti, Nicola Persico, Bruno Battaglia, Paolo Busacchi, Paolo Casadio, Roberto Paradisi, Stefano Venturoli Tags: Original Research Source Type: research

Evaluation of the efficacy of Fructus agni casti in women with severe primary dysmenorrhea: A prospective comparative Doppler study
Abstract AimThe aim of this case–control study was to compare the efficacy of ethinyl estradiol/drospirenone and Fructus agni casti in women with severe primary dysmenorrhea measuring uterine artery blood flow via Doppler ultrasonography. MethodsA total of 60 women with severe primary dysmenorrhea and 30 healthy women (control) were included in this study. Thirty patients were treated with ethinyl estradiol 0.03 mg/drospirenone (group 1) and another 30 were treated with Fructus agni casti (group 2) during three menstrual cycles. Before and at the end of third month of therapy visual analog scale (VAS) scores, ...
Source: Journal of Obstetrics and Gynaecology Research - November 18, 2013 Category: OBGYN Authors: Ayse Nur Aksoy, Ilay Gözükara, Suna Kabil Kucur Tags: Original Article Source Type: research

Basal and Meal-Stimulated Ghrelin, PYY, CCK Levels and Satiety in Lean Women With Polycystic Ovary Syndrome: Effect of Low-Dose Oral Contraceptive.
Conclusions:Basal and stimulated hunger and satiety hormones in lean PCOS patients are not different from lean healthy women, except for a lower meal-stimulated ghrelin response. Short-term use of a low-dose oral contraceptive does not have an effect on appetite regulation of PCOS. PMID: 24001751 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 3, 2013 Category: Endocrinology Authors: Arusoglu G, Koksal G, Cinar N, Tapan S, Aksoy DY, Yildiz BO Tags: J Clin Endocrinol Metab Source Type: research

One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
Conclusions The low-dose, 0.25 mg DRSP/0.5 mg E2 dose combination met the criteria for endometrial safety and demonstrated a favorable risk/benefit profile in this 1-year, double-blind, randomized study of postmenopausal women. PMID: 23531117 [PubMed - as supplied by publisher] (Source: Climacteric)
Source: Climacteric - May 11, 2013 Category: Geriatrics Authors: Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K Tags: Climacteric Source Type: research

Drospirenone and non‐fatal venous thromboembolism: Is there a risk difference by dosage of Ethinyl‐Estradiol?
ConclusionsWe observed modestly elevated VTE risk with drospirenone, compared to levonorgestrel. The larger VTE incidence‐rate observed in DRSP/EE20 than DRSP/EE30, and the increasing VTE incidence‐rate with levonorgestrel between 2007‐2009 were unexpected.This article is protected by copyright. All rights reserved. (Source: Journal of Thrombosis and Haemostasis)
Source: Journal of Thrombosis and Haemostasis - April 11, 2013 Category: Hematology Authors: Steven T Bird, Joseph A C Delaney, Mahyar Etminan, James M Brophy, Abraham G Hartzema Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Hormonal contraceptives and venous thromboembolism: An epidemiological update
In conclusion, newer generation formulations of hormonal contraceptives, as well as the non-oral hormonal contraceptive, seem to be more thrombogenic than second generation hormonal contraceptives. (Source: Best Practice and Research. Clinical Endocrinology and Metabolism)
Source: Best Practice and Research. Clinical Endocrinology and Metabolism - February 1, 2013 Category: Endocrinology Authors: Genevieve Plu-Bureau, Lorraine Maitrot-Mantelet, Justine Hugon-Rodin, Marianne Canonico Source Type: research

Drospirenone‐containing oral contraceptives and risk of adverse outcomes after myocardial infarction
Abstract Background:The association between oral contraceptives (OC) and myocardial infarction remains controversial. The new generation contraceptive Yasmin (30 µg ethinyl estradiol and 3 mg drospirenone) has a lower estrogen and newer progestin component. To date, there are no data available for the myocardial infarction risk and outcome for drospirenone. We aimed to investigate the effect of Yasmin use on cardiovascular outcomes in patients with acute ST segment elevation myocardial infarction (STEMI) undergoing primary angioplasty. Methods:We retrospectively evaluated 1851 patients who underwent primary angioplas...
Source: Catheterization and Cardiovascular Interventions - January 30, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Can Yucel Karabay, Gonenc Kocabay, Vecih Oduncu, Arzu Kalayci, Ahmet Guler, Ali Karagöz, Ozkan Candan, Ozcan Basaran, Regayip Zehir, Akın İzgi, Ali Metin Esen, Cevat Kırma Tags: Original Study Source Type: research

Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination
Conclusion: Lean women with PCOS have similar body composition compared to healthy women. OC therapy for 6 months in PCOS patients results in an increased total and trunk fat percentage despite no change in clinical anthropometric measures including weight, BMI and WHR. (Source: Contraception)
Source: Contraception - August 14, 2012 Category: OBGYN Authors: Kadriye Aydin, Nese Cinar, Duygu Yazgan Aksoy, Gurkan Bozdag, Bulent Okan Yildiz Tags: Original Research Articles Source Type: research